Surmodics, Inc. Common Stock(SRDX)

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.

SRDX iron condor setups SRDX expected move SRDX IV rank history

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

Snapshot
$42.99
52-Week Range
$25.87 – $43.00
IV Rank (30D)
1.79
Straddle Price
$0.00
P/C Vol Ratio
6.94
Market Cap
$0.6B
Info
Industry (SIC)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841)
Exchange
XNAS
Market Cap
$0.6B

Surmodics Inc is a provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (IVD) immunoassay tests and microarrays. The company's reportable segments are; Medical Device and In Vitro Diagnostics. Maximum revenue for the company is derived from its Medical Device segment which is involved in the manufacturing and licensing of performance coatings, including surface modification coating technologies and drug-delivery coating technologies. This segment also manufactures vascular intervention medical devices, inc…

Price History
Seasonality
MonthAvg ReturnYears of Data
Jan -9.84% 5
Feb -2.97% 5
Mar -0.89% 5
Apr -5.69% 5
May +7.85% 5
Jun +13.83% 5
Jul +3.90% 5
Aug +0.06% 5
Sep -8.61% 5
Oct -1.69% 5
Nov +11.27% 5
Dec +3.10% 4
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators
SMA 20: $31.72
SMA 50: $30.68
SMA 200: $31.12
Current: $42.98
EMA 12: $36.67
EMA 26: $33.21
MACD: 3.4574 | Signal: 1.8077
BULLISH
ADX (14): 57.34
STRONG TREND
+DI: 53.06
−DI: 14.20
Momentum Oscillators
RSI (14): 85.79
OVERBOUGHT
Stoch %K: 99.54
Stoch %D: 99.03
Williams %R: -0.14
Volume & Volatility
BB Upper: $45.04
BB Lower: $18.40
NEUTRAL
OBV: 11,824,395
Vol SMA 20: 1,021,497
Vol ROC: 4902.00%
ATR: $1.60
True Range: $1.15
HV 20: 145.9%
HV 30: 119.8%
HV 60: 86.9%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:18.393000
Date Range: 2023-11-21T00:00:00 – 2025-11-18T00:00:00
AI Analysis

Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.

Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.

News
Earnings History
5 of 5 under expected move
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2024-07-31 After-Close 9.18% 0.22% 0.02x Within
2024-11-06 Pre-Market 11.02% 2.20% 0.20x Within
2025-01-30 After-Close 14.66% 4.06% 0.28x Within
2025-04-30 After-Close 22.31% 0.24% 0.01x Within
2025-08-08 After-Close 10.73% 7.31% 0.68x Within
Options Activity
IV Rank (30D)
1.79
IV Rank (7D)
100
Avg IV
66.9%
Straddle (30D)
$0.00
Straddle (7D)
$0.00
P/C Volume
6.94
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Volatility Surface

Enter a ticker to render the implied volatility surface.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Beta (1Y vs SPY)
0.62
Correlation (SPY)
8.2%
R²
0.01
Ann. Volatility
82.6%
SPY Volatility
10.9%

Low volatility - stock moves less than market

Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2025-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

4 filers58,105 shares$1.74M value
# Filer Shares Value % of Total % of Float Period
1 Burren Capital Advisors Ltd 33,664 $1.01M 57.94% — 2025-09-30
2 Cubist Systematic Strategies, LLC 21,904 $654.71K 37.70% — 2025-09-30
3 Point72 (DIFC) Ltd 2,526 $75.50K 4.35% — 2025-09-30
4 Essential Partners LLC 11 $327 0.02% — 2025-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period
Insider Activity
Latest: 2025-11-19
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2025-11-19 John D. Manders VP Finance, Corp. Controller Disp (D) −8,155 — EDGAR
2025-11-19 Joseph J. Stich SVP of HR, President IVD Disp (D) −61,631 — EDGAR
2025-11-19 JOSE H BEDOYA Director Disp (D) −30,008 — EDGAR
2025-11-19 Timothy J. Arens Chief Financial Officer Disp (D) −67,299 — EDGAR
2025-11-19 Gary R Maharaj President & CEO Disp (D) −192,056 — EDGAR
2025-11-19 CHARLES W OLSON SVP, Medical Device Coatings Disp (D) −52,278 — EDGAR
2025-11-19 DAVID DANTZKER Director Disp (D) −40,183 — EDGAR
2025-11-19 Lisa Wipperman Heine Director Disp (D) −13,978 — EDGAR
2025-11-19 Gordon S. Weber Sr. VP of Legal, GC and Sec. Disp (D) −21,040 — EDGAR
2025-11-19 SUSAN E KNIGHT Director Disp (D) −37,240 — EDGAR
2025-11-19 TERI WOODWICK SIDES SVP, Vascular Interventions Disp (D) −34,703 — EDGAR
2025-02-20 Lisa Wipperman Heine Director Mixed +525 $30.32 -$28 EDGAR
2025-02-18 JOSE H BEDOYA Director Mixed +1,051 $30.32 -$31 EDGAR
2025-02-18 DAVID DANTZKER Director Mixed +1,059 $30.35 -$11 EDGAR
2025-01-28 SUSAN E KNIGHT Director Mixed +2,092 $31.83 -$24 EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
34 insiders · @ $42.98
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Starboard Principal Co LP 10%+ Owner 1,406,667 $60.46M -$36.55M 1 2012-08-10
2 Starboard Value GP LLC 10%+ Owner 453,178 $19.48M -$11.30M 1 2012-08-15
3 BRUCE BARCLAY President & CEO 82,255 $3.54M $0 8 2010-02-10
4 LISE W DURAN VP of Research 59,017 $2.54M -$125.8K 12 2010-02-10
5 RONALD B SR KALICH Director 38,278 $1.65M -$91.5K 46 2024-02-12
6 Bryan K Phillips SVP, Gen Counsel & Secretary 36,411 $1.56M -$1.47M 30 2019-12-02
7 PHILIP D ANKENY Interim CEO, Senior VP & CFO 36,369 $1.56M -$148.8K 10 2010-12-02
8 Aron B Anderson VP & Chief Scientific Officer 33,867 $1.46M -$529.7K 15 2010-02-10
9 JOHN A MESLOW Director 31,227 $1.34M $0 6 2010-12-02
10 Thomas A. Greaney COO of Medical Devices 30,013 $1.29M $0 5 2019-11-27
11 KENNETH H KELLER Director 26,800 $1.15M -$491.0K 11 2010-12-02
12 Gregg S Sutton VP of Research and Development 26,363 $1.13M -$1.10M 8 2019-12-02
13 Andrew D. C. LaFrence VP of Finance & CFO 20,486 $880.5K $0 9 2017-11-30
14 STEVEN J KEOUGH Sr VP/Gen Mgr Orth/Chf IP Cnsl 19,943 $857.2K -$874.8K 4 2008-03-25
15 ARTHUR J TIPTON VP, Pres of Pharmaceuticals 17,317 $744.3K $0 7 2010-12-02
16 LOREN R MILLER Vice President and Controller 16,869 $725.0K $0 1 2007-08-15
17 Paul A Lopez VP, President - Ophthamology 16,645 $715.4K -$1.79M 13 2010-02-10
18 GERALD B FISCHER Director 15,557 $668.6K $0 10 2014-12-05
19 JOHN W BENSON Director 14,199 $610.3K $0 14 2015-12-22
20 ROBERT C BUHRMASTER Director 11,672 $501.7K $50.1K 12 2014-02-06
21 Brian L Robey Sr VP, Product Development 10,665 $458.4K $0 9 2010-05-18
22 Shawn mcCormick Director 9,210 $395.8K $0 13 2020-02-18
23 Jan M Webster VP of HR 8,390 $360.6K $0 7 2010-12-02
24 Mark A. Lehman Corporate Controller 6,957 $299.0K -$40.8K 13 2014-11-20
25 Nusrath Sultana VP, Clinical Affairs 6,530 $280.7K $0 5 2022-02-14
26 DOUGLAS P ASTRY Gen Mgr, In Vitro Technologies 6,217 $267.2K -$13.4K 10 2010-02-10
27 TIMOTHY S NELSON Director 6,176 $265.4K $0 2 2014-12-05
28 Eugene C. Rusch VP, Manufacturing 5,000 $214.9K $0 2 2010-12-02
29 MARY K BRAINERD Director 4,263 $183.2K $0 6 2013-11-20
30 Scott R. Ward Director 4,207 $180.8K $0 6 2014-12-05
31 Peter L Ginsberg VPof Bus Devlpmt & Strat Plan 4,000 $171.9K $0 2 2008-05-21
32 Michael J Shoup VP of Qual, Reg & Clinical 2,851 $122.5K -$80.2K 7 2010-02-10
33 Amy E. Seibert Principal Accounting Officer 1,645 $70.7K $0 2 2016-05-02
34 John C. Middleton VP, Drug Del, Product Dev 1,643 $70.6K $0 1 2010-08-03
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
# ETF Provider Weight $ Exposure ETF AUM As Of
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.